View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 14, 2016updated 29 Jul 2022 12:16pm

GTx begins Phase II trial of enobosarm to treat women with stress urinary incontinence

US-based biopharmaceutical firm GTx has started its Phase II clinical trial of enobosarm (GTx-024) to treat postmenopausal women with stress urinary incontinence (SUI).

US-based biopharmaceutical firm GTx has started its Phase II trial of enobosarm (GTx-024) to treat postmenopausal women with stress urinary incontinence (SUI).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

SUI refers to unintentional urination during activities that increase abdominal pressure, such as coughing, sneezing or physical exercise.

The Phase II proof-of-concept trial is the first clinical study to evaluate a selective androgen receptor modulator (SARM) for SUI.

The proof-of-concept trial will assess the effects of orally administered enobosarm 3mg in postmenopausal women with SUI.

Around 35 patients will be enroled in the trial, which will evaluate the safety and efficacy of enobosarm, and the company expects to release top-line results this year.

Beaumont Hospital Urology chief and the principal investigator in the clinical trial Kenneth Peters said: “Given the selective anabolic activity of enobosarm, we are looking forward to evaluating its potential to augment pelvic floor muscle response and potentially improve outcomes for women with stress urinary incontinence.

“I would welcome a safe and effective treatment option, especially since existing non-surgical options are extremely limited and, at times, only marginally effective.”

The trial’s primary endpoint is the change in frequency of daily stress urinary incontinence episodes from baseline to week 12.

Secondary efficacy endpoints will include accepted measurements of voiding, urethral pressure profile and change in pelvic floor muscles as measured by magnetic resonance imaging (MRI).

The initiation of this Phase II trial is supported by preclinical in vivo data showing increases in pelvic floor muscle mass.

This data was acquired following treatment with the company’s SARM compounds, as well as enobosarm clinical trials involving over 1,500 subjects.

According to the company, enobosarm has been found to be generally safe and well tolerated.

After the proof-of-concept trial, the company will determine which GTx SARM compound may receive further development.

The company is also conducting a Phase II trial of enobosarm 18mg in women with androgen receptor positive (AR+), triple negative breast cancer, as well as a Phase II trial of enobosarm 9mg or 18mg in women with estrogen receptor positive (ER+), AR+ breast cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena